BioXcel Therapeutics Announces Acceptance of Abstract at ASCO 2018 Annual Meeting
April 26 2018 - 8:30AM
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage
biopharmaceutical development company utilizing novel artificial
intelligence to identify the next wave of medicines across
neuroscience and immuno-oncology, announced today that it will
present a poster supporting results from a preclinical study of the
Company's BXCL701 and Nektar Therapeutics’ NKTR-214 targeting
pancreatic cancer at the upcoming 2018 American Society for
Clinical Oncology (ASCO) Annual Meeting, being held June 1-5, 2018
in Chicago, IL, USA.
Details of the accepted poster are below:
Abstract #3085 / Poster #299: Efficacy and immune
modulation by BXCL701 a dipeptidyl peptidase inhibitor, NKTR-214 a
CD122-biased immune agonist with PD1 blockade in murine pancreatic
tumors
|
|
Date: |
|
Monday, June 04,
2018 |
|
|
Time: |
|
8:30 AM-11:30 AM
CT |
|
|
Session: |
|
Developmental
Therapeutics- Immunotherapy |
|
|
Location: |
|
Hall A |
In November 2017, BioXcel Therapeutics entered into a research
collaboration with Nektar Therapeutics to explore the novel
combination of Nektar’s NKTR-214, a CD122-biased agonist, and BTI’s
BXCL701, a small molecule immune-modulator and DPP 8/9 and FAP
inhibitor, in preclinical mouse models of pancreatic and prostate
cancer. The discovery collaboration was focused on utilizing the
complementary mechanisms of the two assets to boost the body’s own
immune system and overcome the immunosuppressive mechanisms present
in the tumor microenvironment.
About BioXcel Therapeutics, Inc. (BTI):BioXcel
Therapeutics, Inc. is a clinical stage biopharmaceutical company
focused on drug development that utilizes novel artificial
intelligence to identify the next wave of medicines across
neuroscience and immuno-oncology. The company's drug re-innovation
approach leverages existing approved drugs and/or clinically
validated product candidates together with big data and proprietary
machine learning algorithms to identify new therapeutic indices.
The company's two most advanced clinical development programs are
BXCL501, a sublingual thin film formulation designed for acute
treatment of agitation resulting from neurological and psychiatric
disorders, and BXCL701, an immuno-oncology agent designed for
treatment of a rare form of prostate cancer and for treatment of
pancreatic cancer.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements in this press release include, but
are not limited to, statements that relate to BXCL701’s advancement
and development, the presentation of data at ASCO and other
information that is not historical information. When used herein,
words such as “anticipate”, “being”, “will”, “may”, “continue”, and
similar expressions are intended to identify forward-looking
statements. In addition, any statements or information that refer
to expectations, beliefs, plans, projections, objectives,
performance or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking. All forward-looking statements are based upon
BioXcel’s current expectations and various assumptions. BioXcel
believes there is a reasonable basis for its expectations and
beliefs, but they are inherently uncertain. BioXcel may not
realize its expectations, and its beliefs may not prove correct.
Actual results could differ materially from those described or
implied by such forward-looking statements as a result of various
factors, including, without limitation, market conditions and the
factors described under “Risk Factors” in BioXcel’s prospectus
dated March 7, 2018 and BioXcel’s other filings made with the
Securities and Exchange Commission. Consequently, forward-looking
statements should be regarded solely as BioXcel’s current plans,
estimates and beliefs. Investors should not place undue reliance on
forward-looking statements. BioXcel cannot guarantee future
results, events, levels of activity, performance or achievements.
BioXcel does not undertake and specifically declines any obligation
to update, republish, or revise any forward-looking statements to
reflect new information, future events or circumstances or to
reflect the occurrences of unanticipated events, except as may be
required by law.
Contact Information:BioXcel TherapeuticsThe
Ruth Group Lee Roth646-536-7012lroth@theruthgroup.com
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Sep 2023 to Sep 2024